Table 3

Results of Conventional and Network Meta-Analyses for the Main Efficacy Outcome Response

Medication	TCA	SSRI	SNRI	NRI	Low-Dose SARI	NaSSA	rMAO-A	Hypericum	Placebo
TCA
OR (95% CI)^a		0.95 (0.84–1.08)	0.83 (0.37–1.89)	na	1.43 (0.60–3.42)	3.83 (1.67–8.75)	1.65 (1.16–2.34)	0.87 (0.54–1.41)	1.67 (1.24–2.25)
No. of studies; I², %; P value^b		18; 0; .45;	2; 55; 0.14	na	2; 79; .03	1	3; 0; .79;	2; 24; 0.25;	8; 25; .23;
OR (95% CI)^c		1.04 (0.88–1.21)	1.00 (0.71–1.40)	1.23 (0.73–2.14)	0.97 (0.65–1.47)	1.55 (1.11–2.18)	1.65 (1.10–2.45)	0.86 (0.67–1.10)	1.75 (1.42–2.15)
SSRI
OR (95% CI)^a	1.05 (0.93–1.19)		0.92 (0.67–1.25)	1.18 (0.85–1.65)	na	1.05 (0.54–2.03)	na	0.88 (0.63–1.23)	1.57 (1.31–1.89)
No. of studies; I², %; P value^b	18; 0; .45		4; 64; .04	1	na	3; 60; .08	na	6; 46; .10	7; 0; .83
OR (95% CI)^c	0.97 (0.82–1.13)		0.96 (0.71–1.29)	1.19 (0.71–2.04)	0.94 (0.63–1.43)	1.50 (1.06–2.11)	1.60 (1.03–2.54)	0.83 (0.66–1.04)	1.69 (1.40–2.04)
SNRI
OR (95% CI)^a	1.20 (0.53–2.72)	1.09 (0.79–1.49)		na	na	na	na	na	1.94 (0.96–3.93)
No. of studies; I², %; P value^b	2; 55; .14	4; 64; .04		na	na	na	na	na	1
OR (95% CI)^c	1.00 (0.72–1.41)	1.03 (0.77–1.42)		1.23 (0.67–2.28)	0.97 (0.60–1.63)	1.55 (1.02–2.45)	1.65 (0.98–2,80)	0.86 (0.59–1.24)	1.75 (1.24–2.47)
NRI
OR (95% CI)^a	na	0.84 (0.61–1.18)	na		na	na	na	na	na
No. of studies; I², %; P value^b	na	1	na		na	na	na	na	na
OR (95% CI)^c	0.60 (0.41–0.91)	0.63 (0.41–0.87)	0.61 (0.36–1.02)		0.79 (0.41–1.57)	0.94 (0.58–1.54)	1.34 (0.66–2.70)	0.52 (0.32–0.84)	1.42 (0.81–2.49)
Low-dose SARI
OR (95% CI)^a	0.70 (0.29–1.67)	na	na	na		2.11 (1.37–3.25)	na	na	na
No. of studies; I², %; P value^b	2; 79; .03	na	na	na		4; 0; .56	na	na	na
OR (95% CI)^c	1.03 (0.68–1.55)	1.06 (0.70–1.58)	1.03 (0.61–1.67)	1.26 (0.63–2.47)		1.60 (1.07–2.42)	1.70 (0.96–2.89)	0.89 (0.58–1.38)	1.80 (1.17–2.76)
NaSSA
OR (95% CI)^a	0.26 (0.11–0.60)	0.95 (0.49–1.85)	na	na	0.47 (0.31–0.73)		1.07 (0.49–2.34)	na	1.34 (0.85–2.10)
No. of studies; I², %; P value^b	1	3; 60; .08	na	na	4; 0; .56		1	na	2; 0; .98
OR (95% CI)^c	0.64 (0.46–0.93)	0.67 (0.47–0.95)	0.64 (0.41–0.98)	0.79 (0.42–1.45)	0.63 (0.41–0.93)		1.06 (0.65–1.72)	0.55 (0.37–0.82)	1.13 (0.78–1.62)
rMAO-A
OR (95% CI)^a	0.61 (0.43–0.86)	na	na	na	na	0.93 (0.43–2.03)		na	na
No. of studies; I², %; P value^b	3; 0; .79	na	na	na	na	1		na	na
OR (95% CI)^c	0.61 (0.41–0.91)	0.63 (0.41–0.97)	0.61 (0.36–1.02)	0.74 (0.37–1.52)	0.59 (0.35–1.04)	0.94 (0.58–1.54)		0.52 (0.32–0.84)	1.06 (0.67–1.66)
Hypericum
OR (95% CI)^a	1.15 (0.71–1.85)	1.14 (0.81–1.59)	na	na	na	na	na		2.02 (1.41–2.88)
No. of studies; I², %; P value^b	2; 24; .25	6; 43; .12	na	na	na	na	na		9; 43; .08
OR (95% CI)^c	1.16 (0.81–1.50)	1.20 (0.96–1.51)	1.16 (0.80–1.68)	1.43 (0.81–2.64)	1.13 (0.72–1.73)	1.80 (1.21. 2.67)	1.92 (1.20–3.16)		2.03 (1.63–2.53)

CI = confidence interval; CI = credible interval; hypericum = extract from Hypericum perforatum L.; rMAO-A = reversible inhibitor of monoaminoxidase A (moclobemide, minaprine); na = not available; NaSSA = noradrenergic and specific serotonergic antidepressive agent (mianserin, mirtazapine); NRI = noradrenaline reuptake inhibitor (reboxetine); OR = odds ratio; SARI = serotonin (5-HT₂) antagonist and reuptake inhibitor (trazodone); SNRI = serotonin-noradrenaline reuptake inhibitor (venlafaxine); SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic and tetracyclic antidepressant.

Note: Odds ratios >1 indicate more study discontinuation in patients receiving the treatment given in the row heading.
↵a Conventional meta-analysis of within-study comparisons with pooled odds ratios.
↵b Studies with direct comparisons available, with I² value and P value from the χ² test for heterogeneity.
↵c From network meta-analysis.